TD Cowen projects that with Eli Lilly (NYSE ... semaglutide will be competing neck and neck in the GLP-1 market in 2030 with their products, Mounjaro/ Zepbound and Ozempic/ Wegovy, respectively.

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...

This is given that its GLP-1 therapies, including Mounjaro and Zepbound ... receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose ...

Feb 20 - Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs ... transformative products like Mounjaro and Zepbound, which have ...

Lilly figures it won't have to be conservative with launch supplies of orforglipron, unlike the situation with Mounjaro and Zebpound. For its injectable GLP-1s, which were met with immense ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli ... billion. Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared ...

In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as Eli ... recent GLP-1 revenue results missed heightened expectations. We view Lilly’s Mounjaro ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the ...

Feb 20 - Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its February monthly ... Buoyed by transformative products like ...

These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big ... Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, has ...